FDA Approves Adamis Pharmaceuticals’ EpiPen Competitor

Amid a firestorm of controversy surrounding Mylan’s EpiPen, the FDA has approved an alternative.

San Diego-based Adamis Pharmaceuticals announced the FDA approved Sympeji, its single-dose epinephrine injectable candidate for severe allergic reactions.

Mylan’s response to potential competitors has been a source of controversy. In April, Sanofi sued the drugmaker, alleging its anticompetitive practices kept the Auvi-Q, Sanofi’s competitor, from gaining traction within the market, costing it millions in lost sales while the EpiPen maintained 90 percent command of the auto-injector market. — Zack Budryk